AI Article Synopsis
- The study analyzed the CD4+/CD8+ ratio in people with HIV who switched from a standard treatment to a long-acting combination of cabotegravir and rilpivirine.
- Over the course of one year, participants showed a notable improvement in their CD4+/CD8+ ratio, indicating better immune health.
- The results suggest that using long-acting therapy could help improve immune recovery in those already experienced with HIV treatment.
Article Abstract
Our study assessed the CD4+/CD8+ ratio in people with HIV (PWH) switching from a second-generation integrase inhibitor regimen to long-acting cabotegravir (CAB) and rilpivirine (RPV). Over one year, we observed a significant improvement in the CD4+/CD8+ ratio; In addition, our data showed that time spent in CAB+RPV was significantly associated with an increased CD4+/CD8+ ratio. These findings suggest that long-acting therapy may enhance immune recovery, also in treatment-experienced PWH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QAD.0000000000003984 | DOI Listing |
Publication Analysis
Top Keywords
cd4+/cd8+ ratio
12
second-generation integrase
8
integrase inhibitor
8
inhibitor regimen
8
regimen long-acting
8
long-acting cabotegravir
8
cd4+/cd8+
4
cd4+/cd8+ improvement
4
improvement switch
4
switch second-generation
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!